References
- Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol 2015;8:479-501
- Tricco AC, Strifler L, Veroniki AA, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open 2015;5:e009183
- Hew MJ, Sestini P, Irving LB. How safe are anticholinergic drugs in patients with COPD? Med J Aust 2009;190:468-9
- Kelleher D, Preece A, Mehta R, et al. Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 2011;38(Suppl 55):140s
- Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84:417-23
- Yamagata E, Hashimoto K, Tohda Y. Long-term (52 weeks) safety and tolerability of umeclidinium in Japanese patients with chronic obstructive pulmonary disease. Curr Med Res Opin, 2016;32, published online, doi: 10.1185/03007995.2016.1140029
- Antonelli Incalzi R, Corsonello A, Pedone C, et al.; on behalf of the Extrapulmonary Consequences of COPD in the Elderly Study Investigators. Chronic renal failure. A neglected comorbidity of COPD. Chest 2010;137:831-7
- Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD010115
- Rottenkolber M, Rottenkolber D, Fischer R, et al. Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients. Respir Med 2014;108:1075-90
- Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013;173:1175-85
- Tsai MJ, Huang YB, Chao HC, et al. Long-acting inhaled bronchodilators and risk of vascular events in patients with chronic obstructive pulmonary disease in Taiwan population. Medicine (Balt) 2015;94:e2306
- Komase Y, Asako A, Kobayashi A, et al. Ease-of-use and preference for the ELLIPTA dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older. Int J Chron Obstruct Pulmon Dis 2014;9:1365-75